What is the share price of Acutaas Chemicals Ltd (ACUTAAS) today?
The share price of ACUTAAS as on 23rd June 2025 is ₹1097.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Acutaas Chemicals Ltd (ACUTAAS) share?
The past returns of Acutaas Chemicals Ltd (ACUTAAS) share are- Past 1 week: 2.10%
- Past 1 month: -5.24%
- Past 3 months: -9.42%
- Past 6 months: 2.72%
- Past 1 year: 64.77%
- Past 3 years: 154.59%
- Past 5 years: 134.78%
What are the peers or stocks similar to Acutaas Chemicals Ltd (ACUTAAS)?
The peers or stocks similar to Acutaas Chemicals Ltd (ACUTAAS) include:What is the dividend yield % of Acutaas Chemicals Ltd (ACUTAAS) share?
The current dividend yield of Acutaas Chemicals Ltd (ACUTAAS) is 0.12.What is the market cap of Acutaas Chemicals Ltd (ACUTAAS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Acutaas Chemicals Ltd (ACUTAAS) is ₹8985.93 Cr as of 23rd June 2025.What is the 52 week high and low of Acutaas Chemicals Ltd (ACUTAAS) share?
The 52-week high of Acutaas Chemicals Ltd (ACUTAAS) is ₹1322 and the 52-week low is ₹607.50.What is the PE and PB ratio of Acutaas Chemicals Ltd (ACUTAAS) stock?
The P/E (price-to-earnings) ratio of Acutaas Chemicals Ltd (ACUTAAS) is 56.62. The P/B (price-to-book) ratio is 13.16.Which sector does Acutaas Chemicals Ltd (ACUTAAS) belong to?
Acutaas Chemicals Ltd (ACUTAAS) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Acutaas Chemicals Ltd (ACUTAAS) shares?
You can directly buy Acutaas Chemicals Ltd (ACUTAAS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Acutaas Chemicals Ltd
ACUTAAS Share Price
1,097.603.06% (-34.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ACUTAAS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ACUTAAS Performance & Key Metrics
ACUTAAS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 56.62 | 13.16 | 0.12% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.49 | 6.52 | 0.85% |
100%
Analysts have suggested that investors can buy this stock
from 5 analysts
Price Upside
Earnings Growth
Rev. Growth
ACUTAAS Company Profile
Acutaas Chemicals Limited specializes in manufacturing pharmaceutical intermediates and specialty chemicals for various industries, including pharmaceuticals and agrochemicals, with over 520 products developed across multiple therapeutic areas.
BIOCON
PE Ratio
46.38
46.38
1Y Return
2.92%
2.92%
Buy Reco %
73.33
73.33
ONESOURCE
PE Ratio
-1,241.22
-1,241.22
1Y Return
13.89%
13.89%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
92.42
92.42
1Y Return
1.37%
1.37%
Buy Reco %
66.67
66.67
PANACEABIO
PE Ratio
-303.73
-303.73
1Y Return
211.37%
211.37%
Buy Reco %
0.00
0.00
HESTERBIO
PE Ratio
54.42
54.42
1Y Return
32.19%
32.19%
Buy Reco %
0.00
0.00
ACUTAAS Sentiment Analysis
ACUTAAS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ACUTAAS Stock Summary · May 2025
The company has achieved a remarkable milestone by surpassing INR 1,000 crore in revenue for FY '25, driven by strong performance in its pharmaceutical intermediates and a robust CDMO pipeline. Management anticipates a 25% revenue growth for FY '26, bolstered by new contracts and expanding operations in Japan, despite facing challenges in the Specialty Chemicals segment and sluggish demand in certain areas. With zero debt and a commitment to maintaining a strong financial position, the company is investing INR 200 crores in capital expenditures to enhance production capabilities. While navigating macroeconomic risks, particularly related to tariffs, the focus on long-term supply contracts and operational efficiency positions the company favorably for future growth.
ACUTAAS Stock Growth Drivers
ACUTAAS Stock Growth Drivers
9Significant Revenue Milestone
Ami Organics has achieved a significant milestone by surpassing the INR1,000 crore revenue threshold in
Strategic Positioning in Pharmaceuticals
The company is strategically positioned to benefit from India's growing recognition as an alternative to
ACUTAAS Stock Challenges
ACUTAAS Stock Challenges
2Stagnation in Specialty Chemicals Segment
The Specialty Chemicals segment reported flat revenue of INR 36 crores in Q4 FY '25,
Seasonal Revenue Weakness
The company highlighted that Q1 is typically their weakest quarter, with revenue expected to increase
ACUTAAS Forecast
ACUTAAS Forecasts
Price
Revenue
Earnings
ACUTAAS Share Price Forecast
ACUTAAS Share Price Forecast
2025
Current
₹1,097.60
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,097.60
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ACUTAAS Company Revenue Forecast
ACUTAAS Company Revenue Forecast
2025
Current
₹1.02
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.02
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ACUTAAS Stock EPS (Earnings Per Share) Forecast
ACUTAAS Stock EPS (Earnings Per Share) Forecast
2025
Current
₹9.91
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹9.91
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ACUTAAS
ACUTAAS
Income
Balance Sheet
Cash Flow
Annual Normal View
ACUTAAS Income Statement
ACUTAAS Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 160.47 | 191.18 | 238.89 | 242.48 | 341.99 | 522.90 | 621.05 | 724.96 | 1,023.80 | 1,023.80 | ||||||||||
Raw Materials | 94.75 | 114.72 | 151.95 | 137.96 | 174.87 | 282.33 | 345.85 | 440.17 | 774.80 | 774.80 | ||||||||||
| Power & Fuel Cost | 1.00 | 1.27 | 4.14 | 4.54 | 5.26 | 21.40 | 22.28 | 25.82 | ||||||||||||
| Employee Cost | 7.38 | 9.89 | 8.54 | 12.95 | 21.01 | 41.37 | 48.84 | 63.11 | ||||||||||||
| Selling & Administrative Expenses | 17.60 | 12.56 | 14.77 | 15.38 | 12.13 | 27.34 | 36.69 | 33.12 | ||||||||||||
| Operating & Other expenses | 16.40 | 19.26 | 17.03 | 27.79 | 47.18 | 42.51 | 40.46 | 58.85 | ||||||||||||
EBITDA | 23.34 | 33.48 | 42.46 | 43.86 | 81.54 | 107.95 | 126.93 | 103.89 | 249.00 | 249.00 | ||||||||||
| Depreciation/Amortization | 1.37 | 1.91 | 2.60 | 3.52 | 4.19 | 10.08 | 12.34 | 16.06 | 26.62 | 26.63 | ||||||||||
| PBIT | 21.97 | 31.57 | 39.86 | 40.34 | 77.35 | 97.87 | 114.59 | 87.83 | 222.38 | 222.37 | ||||||||||
| Interest & Other Items | 3.30 | 3.23 | 4.75 | 5.59 | 5.62 | 6.41 | 2.41 | 5.94 | 6.22 | 6.22 | ||||||||||
| PBT | 18.67 | 28.34 | 35.11 | 34.75 | 71.73 | 91.46 | 112.18 | 81.89 | 216.16 | 216.15 | ||||||||||
| Taxes & Other Items | 6.63 | 9.86 | 11.81 | 7.29 | 17.72 | 19.50 | 28.88 | 39.14 | 57.45 | 57.44 | ||||||||||
| Net Income | 12.04 | 18.48 | 23.30 | 27.46 | 54.01 | 71.96 | 83.30 | 42.75 | 158.71 | 158.71 | ||||||||||
| EPS | 1.91 | 2.93 | 3.70 | 4.36 | 8.57 | 10.59 | 11.43 | 5.83 | 9.91 | 21.52 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.13 | 0.26 | 0.15 | 0.07 |
ACUTAAS Company Updates
FY 2025FY 2025
Investor Presentation
May 2PDF
Jan 28PDF
Oct 29PDF
ACUTAAS Stock Peers
ACUTAAS Past Performance & Peer Comparison
ACUTAAS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation-basic on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Acutaas Chemicals Ltd | 56.62 | 13.16 | 0.12% |
| Biocon Ltd | 46.38 | 1.86 | 0.32% |
| Onesource Specialty Pharma Ltd | -1,241.22 | 56.33 | — |
| Sai Life Sciences Ltd | 92.42 | 16.12 | — |
ACUTAAS Stock Price Comparison
Compare ACUTAAS with any stock or ETFCompare ACUTAAS with any stock or ETF
ACUTAAS
ACUTAAS Holdings
ACUTAAS Shareholdings
ACUTAAS Promoter Holdings Trend
ACUTAAS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ACUTAAS Institutional Holdings Trend
ACUTAAS Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 1.07%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ACUTAAS Shareholding Pattern
ACUTAAS Shareholding Pattern
ACUTAAS Shareholding History
ACUTAAS Shareholding History
Foreign Institutions
Mutual Funds Invested in ACUTAAS
Mutual Funds Invested in ACUTAAS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Acutaas Chemicals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.0154% | Percentage of the fund’s portfolio invested in the stock 0.87% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/88 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7722% | Percentage of the fund’s portfolio invested in the stock 0.90% | Change in the portfolio weight of the stock over the last 3 months 0.90% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 47/79 (+24) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2972% | Percentage of the fund’s portfolio invested in the stock 3.19% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/32 (+2) |
Compare 3-month MF holding change on Screener
smallcases containing ACUTAAS stock
smallcases containing ACUTAAS stock
Looks like this stock is not in any smallcase yet.
ACUTAAS Events
ACUTAAS Events
ACUTAAS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ACUTAAS Dividend Trend
No dividend trend available
ACUTAAS Upcoming Dividends
ACUTAAS Upcoming Dividends
No upcoming dividends are available
ACUTAAS Past Dividends
ACUTAAS Past Dividends
Cash Dividend
Ex DateEx DateSep 13, 2024
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateJul 29, 2022
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Jul 29, 2022
ACUTAAS Stock News & Opinions
ACUTAAS Stock News & Opinions
Articles & Videos
Spotlight
Ami Organics jumps after Q4 PAT soars to Rs 627 cr
Revenue from operations jumped 37.13% year on year to Rs 308.48 crore during the quarter ended 31st March 2025. Profit before tax (PBT) soared 122.66% to Rs 82.83 crore in Q4 FY25 as compared with Rs 37.20 crore in Q4 FY24. EBITDA stood at Rs 85 crore, registering the growth of 96.8% as compared with Rs 432 crore in Q4 FY24. EBITDA margin was at 27.5% in Q4 FY25 as against 19.2% in Q4 FY24. In Q4 FY25, export stood at 74% and domestic business was at 26%. Naresh Patel, executive chairman & managing director, Ami Organics, said, 'I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed Rs 1,000 crore in revenue'a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions. Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth.' Meanwhile, the company's board recommended of final dividend of Rs 1.5 per equity share for FY25 Ami Organics headquartered at Surat, is a research and development (R&D) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and chemicals for New Chemical Entities (NCE), and other specialty chemicals.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Ami Organics consolidated net profit rises 148.43% in the March 2025 quarter
Net profit of Ami Organics rose 148.43% to Rs 62.48 crore in the quarter ended March 2025 as against Rs 25.15 crore during the previous quarter ended March 2024. Sales rose 37.13% to Rs 308.48 crore in the quarter ended March 2025 as against Rs 224.96 crore during the previous quarter ended March 2024. For the full year,net profit rose 271.08% to Rs 158.71 crore in the year ended March 2025 as against Rs 42.77 crore during the previous year ended March 2024. Sales rose 40.34% to Rs 1006.88 crore in the year ended March 2025 as against Rs 717.47 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales308.48224.96 37 1006.88717.47 40 OPM %27.5419.19 -23.0517.91 - PBDT90.1342.43 112 242.78130.04 87 PBT82.8337.53 121 216.16113.98 90 NP62.4825.15 148 158.7142.77 271 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of AMI Organics recommends final dividend
AMI Organics announced that the Board of Directors of the Company at its meeting held on 2 May 2025, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 30%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
AMI Organics to hold board meeting
AMI Organics will hold a meeting of the Board of Directors of the Company on 2 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ami Organics' Unit II receives Japan PMDA nod for GMP compliance
Ami Organics' manufacturing facility, Unit II situated at Ankleshwar, which is involved in manufacturing of various intermediates for Active Pharmaceuticals Ingredients, has received Good Manufacturing Practices (GMP) by Pharmaceutical and Medical Devices Agency, Japan (PMDA). Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
AMI Organics to hold EGM
AMI Organics announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Board of Ami Organics approves change in company name to Acutaas Chemicals
The Board of Ami Organics at its meeting held on 16 April 2025 has approved the change in the name of the Company from 'Ami Organics' to 'Acutaas Chemicals', and the consequential alteration the Memorandum of Association and Articles of Association to give effect to the same. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Ami Organics commissions 10.8 MW DC solar power plant
Ami Organics announced the full commissioning of its 10.8 MW DC solar power plant. The solar facility, located at Pratapnagar, Nandod, Narmada District, Gujarat, India, comprises two captive solar plants, each with a capacity of 5.4 MW. Speaking on this significant achievement, Naresh Patel, Chairman and Managing Director of Ami Organics Limited, stated: 'The successful commissioning of our 10.8MW solar power plant marks a crucial step in our journey towards a greener and more sustainable future. This project not only strengthens our commitment to environmental responsibility but also enhances our operational efficiency and cost-effectiveness. With our continued investment in renewable energy, we aim to make substantial progress in reducing our dependence on conventional power sources and moving towards a cleaner, and more sustainable energy portfolio.'Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
AMI Organics announces board meeting date
AMI Organics will hold a meeting of the Board of Directors of the Company on 21 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Board of Ami Organics to consider stock split
The Board of Ami Organics will meet on 21 February 2025 to consider the proposal for alteration in the share capital of the Company by way of sub-division / split of the existing equity shares of the face value Rs 10/- each. Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 24.86%, vs industry avg of 19.23%
Over the last 5 years, market share increased from 3.03% to 3.78%
Over the last 5 years, net income has grown at a yearly rate of 12.91%, vs industry avg of 2.33%